Overcoming obstacles in personalised medicine
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
List view / Grid view
Tune in to this episode to learn how overcoming the key challenges in personalised medicine could transform the future of healthcare.
This study is the first to demonstrate that NSD2 is foundational to the earliest stage of prostate cancer development.
17 July 2024 | By Eurofins Discovery
Join this webinar to hear from Eurofins Discovery on the latest offerings for drug-drug interaction assessments using CRISPR KO/KI MDCKII cell lines
Scientists discovered that, depending on germline variation, CRISPR-based experiments can result in false negatives.
Researchers have developed a new, compact EbCas12a variant that can be packaged into an all-in-one AAV system with its crRNA.
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
CRISPR has transformed gene editing, but still presents challenges in hard-to-transfect cells, such as pluripotent stem cells and primary cells.1 The key to obtaining successful transfection in these cells lies in innovative workflows. Here Georges Müller, CEO and cofounder of SEED Biosciences, shares his perspective on why focusing on editing…
Using cortical organoids, researchers discovered that targeting KCNJ2 could reduce nerve cell death after TBI.
The proof-of-concept study could lead to a cure for HIV that inactivates diverse strains across multiple cellular contexts.
Results from an in vivo CRISPR knockout screen, targeting genes involved in autophagy, could lead to new therapies.
A novel cellular mechanism has been uncovered with the use of CRISPR gene-tiling technology, which could advance oncologic therapies.
Learn how scientists like you are using Namocell single cell sorters through summaries of seven recent peer-reviewed citations.
A novel technology can reduce tumour sizes significantly and improve treatment efficacy when used with existing immunotherapy.
Using CRISPRa to activate genes in readily accessible cells provides an effective and accurate diagnosis of genetic diseases.
AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.